10-Q: Precigen Q3: Papzimeos Approval Drives Commercial Transition

Precigen reports significant Q3 2025 financial shifts, driven by the FDA approval of Papzimeos and a substantial increase in net loss due to warrant reclassification and preferred stock conversion.

Summary

• The FDA granted full approval to Papzimeos (zopapogene imadenovec-drba) in August 2025 for the treatment of adults with recurrent respiratory papillomatosis (RRP), marking the company's transition to a commercial-stage biopharmaceutical entity.
• Total revenues increased by over 200% to $2.9 million for the three months ended September 30, 2025, and by 87.2% to $5.1 million for the nine months ended September 30, 2025, primarily due to a $1.8 million collaboration and licensing revenue recognized from a terminated agreement.
• Net loss for the third quarter of 2025 was $(146.3) million, a significant increase from $(24.0) million in the same period of 2024.
• Net loss attributable to common shareholders for Q3 2025 was $(325.3) million, which includes a $179.0 million non-cash deemed dividend on preferred stock conversion.
• Operating loss for Q3 2025 was $(34.5) million, compared to $(21.3) million in Q3 2024.
• Selling, general and administrative (SG&A) expenses surged by 144% to $24.0 million in Q3 2025, largely driven by commercial readiness efforts for Papzimeos.
• Research and development (R&D) expenses increased by 9% to $12.4 million in Q3 2025, primarily due to manufacturing and regulatory costs for Papzimeos.
• A non-cash expense of $111.5 million was recorded for the change in fair value of warrant liabilities in Q3 2025, prior to their reclassification to equity.
• Secured a 5-year senior secured term loan facility of up to $125.0 million, with an initial tranche of $100.0 million funded in September 2025.
• All Series A Preferred Stock was converted to common stock in September 2025, resulting in 54,937,411 new common shares and the aforementioned $179.0 million non-cash deemed dividend.
• Cash and cash equivalents were $14.3 million, with total liquid assets (cash, cash equivalents, and investments) at $123.6 million as of September 30, 2025.

Sentiment

Score: 4

Explanation: While the FDA approval of Papzimeos is a significant positive, the substantial increase in net loss, driven by non-cash items and high commercialization costs, coupled with the pausing of other clinical programs and ongoing need for capital, indicates significant financial challenges and strategic shifts that introduce uncertainty.

Positives

• Received full FDA approval for Papzimeos (zopapogene imadenovec-drba) in August 2025 for the treatment of adults with RRP, transitioning the company to a commercial-stage biopharmaceutical company.
• Papzimeos is the first immunotherapy approved for RRP, addressing a significant unmet medical need and establishing a new therapeutic paradigm.
• The pivotal Phase 1/2 clinical trial for Papzimeos successfully met primary safety and efficacy endpoints, with 51% (18 out of 35) of study patients achieving Complete Response, which remained durable for over 12 months (median follow-up of 36 months).
• Secured a $100.0 million initial tranche of a $125.0 million senior secured term loan facility in September 2025, providing capital for the commercial launch of Papzimeos and general corporate purposes.
• Total revenues increased by over 200% in Q3 2025 and 87.2% for the nine months ended September 30, 2025, partly due to a one-time $1.8 million collaboration revenue recognition from a terminated agreement.
• Successful conversion of all Series A Preferred Stock to common stock in September 2025, simplifying the capital structure.
• Management believes existing liquid assets of $123.6 million as of September 30, 2025, will allow operations to continue for at least one year from the filing date.

Negatives

• Net loss for Q3 2025 significantly widened to $(146.3) million from $(24.0) million in Q3 2024.
• Net loss attributable to common shareholders increased dramatically to $(325.3) million in Q3 2025, primarily due to a $179.0 million non-cash deemed dividend on preferred stock conversion.
• A substantial non-cash expense of $111.5 million was recorded for the change in fair value of warrant liabilities in Q3 2025.
• Operating loss increased to $(34.5) million in Q3 2025 from $(21.3) million in Q3 2024.
• Selling, general and administrative (SG&A) expenses surged by 144% to $24.0 million in Q3 2025, reflecting high commercialization costs for Papzimeos.
• Accumulated deficit reached $2.3 billion as of September 30, 2025.
• A goodwill impairment charge of $3.9 million was recorded in Q2 2025 related to the Exemplar reporting unit due to projected delays in product and service delivery.
• Enrollment in PRGN-3005 and PRGN-3007 UltraCAR-T clinical trials was paused, and UltraCAR-T spending minimized, as part of a strategic prioritization.
• Exemplar's $5.0 million revolving line of credit with American State Bank matured on November 1, 2025, and was not renewed.

Risks

• Dependence on key individuals and intellectual property for continued operations and development.
• Significant competition from other products and companies in the biopharmaceutical market.
• Uncertainty regarding market acceptance and third-party payor coverage for Papzimeos and future products.
• Technical risks associated with the successful research, development, and clinical/commercial manufacturing of therapeutic product candidates.
• The level of indebtedness and debt service obligations could adversely affect financial condition and reduce cash available for operations and R&D.
• Failure to comply with affirmative and restrictive covenants in the Loan Agreement could result in an event of default, potentially accelerating debt repayment.
• Increased vulnerability to downturns in business, industry, or the economy due to existing indebtedness.
• Potential for future impairment indicators or charges related to goodwill and intangible assets due to market changes or shifts in management's judgments and estimates.
• Inability to raise sufficient additional funds on favorable terms, which could lead to substantial dilution for common shareholders.
• Relinquishing valuable rights to technologies, future revenue streams, research programs, or product candidates if funds are raised through strategic transactions, collaborations, or licensing arrangements.
• Exposure to unforeseen expenses, difficulties, complications, delays, and other unknown factors inherent in the development and commercialization of new products.
• Involvement in litigation or legal matters, including governmental investigations, which could result in adverse judgments, unfavorable settlements, or regulatory action.

Future Outlook

The company's revenue profile is expected to evolve significantly with the commercialization of Papzimeos, with future revenues increasingly dependent on its successful launch and the advancement of proprietary programs. Collaboration revenue is anticipated to remain minimal in the near term, except for specific events or future strategic transactions. Future costs of products will be driven by Papzimeos commercialization, and related expenses will no longer be classified as R&D for adults. SG&A expenses may fluctuate based on scaling corporate functions, strategic asset prioritization, commercialization efforts, and legal outcomes. The company plans to focus on strategic partnerships to further advance its UltraCAR-T programs and will continue PRGN-2009 Phase 2 clinical trials under a CRADA with the NCI. Management believes existing liquid assets will allow operations for at least one year, but the transition to profitability depends on successful commercialization and sufficient revenues, potentially requiring additional capital raises.

Management Comments

• "Precigen is a biopharmaceutical company advancing the next generation of gene and cell therapies with the overall goal of improving outcomes for patients with significant unmet medical needs."
• "Papzimeos is the first immunotherapy approved for the treatment of RRP."
• "The FDA approval of Papzimeos transitions Precigen from a development-stage to a commercial-stage company."
• "Management believes that existing liquid assets as of September 30, 2025 will allow the Company to continue its operations for at least a year from the issuance date of these condensed consolidated financial statements."
• "Our success is dependent upon our ability to continue to raise additional capital in order to fund ongoing research and development, obtain regulatory approval of our products, successfully commercialize our products, generate revenue, meet our obligations, and, ultimately, attain profitable operations."

Industry Context

Precigen's FDA approval of Papzimeos for RRP marks a significant milestone, positioning the company as a commercial-stage biopharmaceutical entity with a first-in-class immunotherapy for a rare disease. This development is poised to disrupt the current RRP treatment landscape, which has historically relied on repeated surgical interventions. The company's strategic shift to prioritize Papzimeos commercialization while seeking partnerships for its UltraCAR-T programs reflects a common industry trend among smaller biotechs to focus resources on lead assets and de-risk other costly clinical developments through collaboration. The substantial increase in SG&A expenses for commercial readiness is typical for companies entering the market with a new therapeutic, indicating a significant investment in establishing sales and marketing infrastructure.

Comparison to Industry Standards

• Papzimeos is the 'first and only FDA-approved therapy for the treatment of adults with RRP,' establishing a new therapeutic paradigm and setting a high benchmark for future competitors in this rare disease space.
• The 51% complete response rate in the pivotal Phase 1/2 trial for Papzimeos, with durability over 12 months (median follow-up of 36 months), demonstrates strong clinical efficacy for a first-in-class treatment for a chronic, debilitating condition, which is highly favorable compared to existing surgical management that does not address the root cause.
• The company's UltraCAR-T platform aims to improve upon current CAR-T manufacturing by enabling overnight, decentralized production, potentially reducing costs and improving cell persistence. This could offer a significant competitive advantage against established CAR-T players like Novartis (Kymriah), Gilead (Yescarta), and Bristol Myers Squibb (Breyanzi) if successfully commercialized, although these programs are currently paused for strategic partnerships.
• The significant increase in SG&A expenses for commercial readiness is consistent with industry standards for biopharmaceutical companies launching a new product, reflecting necessary investments in market entry and infrastructure.

Corporate Governance

Legal Proceedings

• Edward D. Wright, derivatively on behalf of Precigen, Inc. F/K/A Intrexon Corp. v. Alvarez et al: A derivative shareholder action filed in December 2020 in the Circuit Court for Fairfax County, Virginia, related to disclosures about the MBP program. The case was stayed by an order entered on June 14, 2021.
• Kent v. Precigen, Inc.: An individual shareholder lawsuit filed on September 24, 2021, in the Circuit Court for Henrico County, Virginia, demanding inspection of certain books and records related to the MBP program. This action was dismissed by the court in October 2025 due to a lack of activity for the preceding three years.
• Indemnification liability related to the August 2022 sale of Trans Ova: The company is required to indemnify the buyer for certain expenses incurred post-close, not to exceed $5,750. As of September 30, 2025, $3,213 was accrued. In November 2025, an indemnification claim of $737 was received for expenses incurred from January 2024 to September 2025.

Related Party Transactions

• In the August 2024 public offering, 23,588,234 shares of common stock were purchased by related parties and their affiliates, including the Company's Chairman of the Board of Directors and his affiliates, and one of the Company's executive officers.

Stakeholder Impact

• Shareholders: Experienced significant dilution from the conversion of preferred stock (54.9 million new shares) and a substantial increase in net loss per share. Potential for long-term value creation hinges on successful Papzimeos commercialization, but future equity raises could lead to further dilution.
• Patients (RRP): Directly benefit from the FDA approval of Papzimeos, which offers the first immunotherapy for RRP and a new, potentially disease-modifying treatment option.
• Employees: Faced workforce reductions of over 20% in August 2024 and the elimination of ActoBio personnel in 2024. However, increased employee-related costs were incurred due to PSU vesting upon FDA approval.
• Creditors (Lenders): The company secured a new $100 million term loan, increasing its debt obligations. Compliance with debt covenants as of September 30, 2025, is positive for lenders.
• Collaborators/Partners: The termination of the ECC with PTC Therapeutics and the strategic shift to seek partnerships for UltraCAR-T programs indicate evolving relationships and potential new opportunities for collaboration.

Next Steps

• Execute the commercial launch of Papzimeos.
• Advance proprietary programs and bring additional products enabled by technology platforms to market.
• Focus on strategic partnerships to further advance UltraCAR-T programs (PRGN-3005, PRGN-3006, PRGN-3007).
• Continue PRGN-2009 Phase 2 clinical trials under a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI).
• Evaluate the impact of new accounting guidance (ASU 2024-03 and ASU 2023-09) on financial statement disclosures.
• Begin principal payments on long-term debt starting December 31, 2028.
• Address potential future capital requirements through various financing strategies.

Key Dates

Recommendation

The FDA approval of Papzimeos is a monumental achievement, transitioning Precigen into a commercial-stage company with a first-in-class product for RRP. This provides a clear path to potential revenue generation. However, the company faces substantial financial headwinds, including a significantly increased net loss driven by non-cash items and high commercialization costs. The strategic prioritization of the pipeline, pausing other promising programs, and the explicit need for future capital raises introduce considerable uncertainty and execution risk. Investors should hold to observe the initial commercial rollout of Papzimeos and assess the company's ability to manage its burn rate and secure additional non-dilutive financing, as further equity raises could lead to significant dilution.

Keywords

Biopharmaceutical, Gene Therapy, Cell Therapy, Papzimeos, RRP, Recurrent Respiratory Papillomatosis, FDA Approval, AdenoVerse, UltraCAR-T, Commercialization, Debt Financing, Warrants, Preferred Stock Conversion, Q3 2025, 10-Q, Immuno-oncology, Exemplar Genetics